Please login to the form below

Not currently logged in
Email:
Password:

Sepracor and Eisai partner to develop and commercialise Lunesta in Japan

Sepracor signs an agreement with Eisai for the development and commercialisation of its sleep aid product Lunesta  in Japan


US-based Sepracor has signed an agreement with Japanese pharmaceutical firm Eisai for the development and commercialisation of Sepracor's sleep aid treatment Lunesta (eszopiclone) in Japan.

Per the agreement, Eisai will be responsible for completing the remaining clinical trials necessary for attaining marketing approval from the Japanese regulatory authorities, and contingent on regulatory approval, commercialisation of the product in Japan. Sepracor has said that the Japanese marketing application will be submitted in 2010/2011.

Sepracor will receive an initial milestone payment and subsequent payments upon accomplishment of various development, regulatory and pricing milestones, as well as royalties on product sales and compensation for providing the product's active ingredient.

Lunesta has been commercially available in the US since 2005 for the treatment of insomnia and posted sales of USD 566.8m in FY06. The sedative hypnotic market in Japan was valued at around USD 500m in 2006.

30th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics